STRICTLY PRIVATE AND CONFIDENTIAL

1QUARTERLY TECH REPORT – Q1: HEALTHTECH

2QUARTERLY TECH REPORT – Q1: HEALTHTECH

DEEP DOMAIN EXPERTISE IN THREE INTER-RELATED SECTORS… …AND AN INTERNATIONAL TRACK RECORD

A MARKET-LEADING CORPORATE FINANCE ADVISORY FIRM… …WITH GLOBAL REACH

•

•

•

•

•

•

•

3QUARTERLY TECH REPORT – Q1: HEALTHTECH

LAST

12 M

ON

TH S

HA

RE P

RIC

E P

ER

FO

RM

AN

CE

Q1 2016 PERFORMANCE

4QUARTERLY TECH REPORT – Q1: HEALTHTECHLA

ST

12 M

ON

THS

Q1 2

016

HEALTHCARE IT - EUROPE HEALTHCARE IT - US BIOPHARMA IT

5QUARTERLY TECH REPORT – Q1: HEALTHTECH

COMPANYIPO

DATEDESCRIPTION

RAISED ($M)

INDICATIVE PRICE RANGE ($)

IPO LISTING PRICE ($)

INCREASE VS. RANGE

DAY 1 INCREASE

CURRENT INCREASE(1)

CURRENT EV ($M)

EV / REVENUE 2016E

EV / EBITDA 2016E

6QUARTERLY TECH REPORT – Q1: HEALTHTECH

REVENUE GROWTH (2016-17E) EV / REVENUE 2016E

EBITDA MARGIN 2016E EV / EBITDA 2016E

7

LTM Q1 2016

% CHANGE

LTM Q1 2016

% CHANGE

QUARTERLY TECH REPORT – Q1: HEALTHTECH

8QUARTERLY TECH REPORT – Q1: HEALTHTECH

NU

MB

ER

OF D

EA

LS

TOTA

L D

ISC

LOSED

DEA

L V

ALU

E (

$M

)

9QUARTERLY TECH REPORT – Q1: HEALTHTECH

DATE BUYER TARGET EV ($M) EV/REVENUE EV/EBITDA COMPANY DESCRIPTIONTARGET

LOCATION

10QUARTERLY TECH REPORT – Q1: HEALTHTECH

DATE COMPANYTYPE OF ROUND

FUNDSRAISED ($M)

INVESTOR PARTICIPATION COMPANY DESCRIPTIONCOMPANYLOCATION

11

OPERATING METRICS VALUATION METRICS

PRICE % OF 52 MARKET TOTAL NET ENTERPRISE REVENUE REV. GROWTH GROSS MARGIN REVENUE EBITDA

COMPANY (31-MAR-16) WEEK HIGH CAP CASH DEBT VALUE CY2016 CY16-17 HISTORICAL CY2016 CY2017 CY2016 CY2017 CY2016 CY2017

GENERALISTS WITH SIGNIFICANT HEALTHTECH EXPOSURE

HEALTHCARE IT - EUROPE

HEALTHCARE IT - US

BIOPHARMA IT

EBITDA MARGIN

QUARTERLY TECH REPORT – Q1: HEALTHTECH

12QUARTERLY TECH REPORT – Q1: HEALTHTECH

MANAGER - LONDON PARTNER – NEW YORKPARTNER – LONDON PARTNER – NEW YORK PARTNER – APAC